|
市場調査レポート
商品コード
1150171
心臓安全性サービスの世界市場規模、シェア、産業動向分析レポート:タイプ別、エンドユーザー別、サービスタイプ別、地域別展望と予測、2022年~2028年Global Cardiac Safety Services Market Size, Share & Industry Trends Analysis Report By Type, By End User, By Type of Service, By Regional Outlook and Forecast, 2022 - 2028 |
||||||
心臓安全性サービスの世界市場規模、シェア、産業動向分析レポート:タイプ別、エンドユーザー別、サービスタイプ別、地域別展望と予測、2022年~2028年 |
出版日: 2022年09月30日
発行: KBV Research
ページ情報: 英文 212 Pages
納期: 即納可能
|
世界の心臓安全性サービス市場規模は、2028年までに11億米ドルに達し、予測期間中にCAGR11.1%の市場成長率で上昇すると予測されています。
心臓、血管、血液成分など、心血管系のすべての要素は、心血管系と非心血管系の両方の医薬品を含む心血管系安全性負債の影響を受けます。心血管系の副作用は、機能的なものと構造的なもの(病理組織学など)があり、急性または慢性治療後に起こる可能性があります。
世間の目が厳しくなり、ビジネスコストが上昇し、規制当局のリソースが限られている現在、効果的かつ安全な医薬品開発の必要性は、これまで以上に高まっています。年間1790万人が死亡する心血管系疾患(CVD)は、世界で最も一般的な死因となっています。脳血管疾患、冠状動脈性心臓疾患、リウマチ性心臓疾患などは、CVDと呼ばれる心臓や血管の疾患のカテゴリーに含まれます。
COVID-19影響度分析
このため、製薬業界や医療保険業界は、より良いサービスを提供するために、必要な変更を行うようになりました。また、医学の進化に伴い、心臓の健康を専門とする多くの研究機関や組織の関与が必要となっています。コロナウイルス関連の大惨事は、持病のある患者を多数死なせ、心臓安全性サービスに影響を及ぼしました。COVID-19の市場開拓を精力的に進めた結果、心臓安全対策サービス市場全体に好影響を及ぼしました。
市場の成長要因
バイオシミラーやバイオロジクスの研究の増加
多くの企業が、生物学的製剤やバイオシミラー化合物の創製に大きな投資を行っています。探索段階では、ペプチド、タンパク質、モノクローナル抗体などの生物製剤が治療薬候補の半分以上を占めています。製薬会社やバイオ医薬品会社は、新規の生物製剤を開発中、あるいはパイプラインにあるため、その研究開発に多額の資金を投じています。また、バイオシミラー医薬品は、特許を取得している生物学的製剤の後発品であるため、厳しい規制の対象とはならないため、価格が低く抑えられています。
一般人口におけるEchホルターサービスの高い普及率
ECGホルターの普及は、高齢者の増加や心血管疾患の発生率の増加が主な原因となっています。Health System Trackerが発表したデータによると、米国では心臓病が死亡原因のトップです。こうした理由から、心拍を即座に検出し、常に心拍を監視する装置が必要とされています。過去数年間、ヘルスケアシステムはECGモニタリング機器を採用し、心臓の活動に異常がないかを調べています。
市場抑制要因
臨床試験のための有資格者不足
医薬品、バイオテクノロジー、医療機器の研究開発アウトソーシング業界は、常に変化しています。高品質のサービスを提供し、許容されるラボの手順を守り、医療機器や医薬品の研究開発技術や手法の進歩に対応するためには、高度なスキルを持つ専門家が必要となります。CROは、バイオテクノロジー、製薬、医療機器企業、研究・学術機関と、訓練を受けた経験豊富な科学者の獲得で競合しており、高いスキルを持つ人材の獲得と維持が困難な状況にあります。
タイプ別展望
心臓安全性サービス市場は、タイプ別に統合型とスタンドアロン型に分けられます。統合型セグメントは、2021年に最も高い収益シェアで心臓安全性サービス市場を独占しました。これらの最先端のコアラボサービスは、イメージング、TQT、およびプロファイルQTテストを含む、フルレンジの心臓安全性サービスを提供します。心拍とリズムのリアルタイム評価を支援するため、ターゲット外の心血管負債にも目を配り、免許を持つ看護師の監督のもと、現場で多チャンネルテレメトリーを実施します。
サービスの種類別展望
心臓安全性サービス市場は、サービスの種類によって、ECG/ホルター測定、血圧測定、心血管イメージング、QT検査、およびその他のサービスに分けられます。2021年の心臓安全性サービス市場では、ECG/ホルター測定分野が最大の収益シェアを示しています。スマートウォッチやその他のパーソナルエレクトロニクスは、心電図モニタリングを提供します。ホルターモニターと呼ばれる小型のポータブルガジェットは、心拍を捉えるために使用されます。異常な心拍(不整脈)を特定し、その可能性を評価するために採用されます。
エンドユーザーの展望
心臓安全性サービス市場は、エンドユーザーに基づき、製薬・バイオ製薬会社と受託研究機関に分類されます。契約研究機関セグメントは、2021年に心臓安全性サービス市場でかなりの収益シェアを調達しました。臨床試験は、製薬、医療機器、バイオテクノロジー企業、および学術機関、政府機関、財団のために、契約研究機関(CRO)によって実施されます。
地域別の展望
地域別に見ると、心臓安全装置は北米、欧州、アジア太平洋、LAMEAで分析されています。北米地域は、2021年の心臓安全性サービス市場において、最も高い収益シェアを獲得しました。これは、同地域の臨床研究数が増加しており、心臓安全性サービスに対する需要が高まっているためです。心血管疾患(CVD)や冠状動脈性心臓病(CHD)を患う人の増加により、同地域の薬剤開発や研究調査が加速しています。
市場参入企業がとる主な戦略は買収です。Cardinalマトリックスで提示された分析によると、Pharmaceutical Product Development, Inc.が心臓安全性サービス市場における主要な先駆者です。Koninklijke Philips N.V.、Laboratory Corporation of America Holdings、IQVIA Holdings, Inc.などの企業は、心臓安全性サービス市場における主要な革新者の一人です。
List of Figures
The Global Cardiac Safety Services Market size is expected to reach $1.1 billion by 2028, rising at a market growth of 11.1% CAGR during the forecast period.
Cardiac safety services assist and design clinical studies & trials and other research necessary for the monitoring of heart safety. These are primarily concerned with tracking the full cardiac safety profile through all clinical trial phases, from Phase I through Phase IV. Guidelines and regulations given by most major and recognized medical authorities of various countries and other regulating agencies are followed while developing cardiac safety clinical trials and studies.
These services include physiologic stress testing, non-invasive cardiac imaging, platelet aggregation, ambulatory blood pressure monitoring, and other services in addition to the QT tests. Due to the grouping of services with an emphasis on end-to-end development, integrated services that provide cardiac safety services are generally favored over standalone services because of the peculiarity of standalone services.
All elements of the cardiovascular system, including the heart, blood vessels, and blood constituents, are affected by cardiovascular safety liabilities, which include both cardiovascular and non-cardiovascular pharmaceuticals. Cardiovascular adverse effects can be functional or structural (such as histopathology) in nature and can happen after acute or chronic treatment.
The need for effective yet secure drug development is more critical than ever in a time of growing public scrutiny, rising business expenses, and limited resources at regulatory agencies. With 17.9 million deaths per year, cardiovascular diseases (CVDs) are the most common cause of death worldwide. Cerebrovascular disease, coronary heart disease, rheumatic heart disease, and other illnesses are among the category of heart and blood vessel disorders known as CVDs.
COVID-19 Impact Analysis
This prompted the pharmaceutical and health insurance industries to make the necessary changes to their offerings in order to include better provisions and facilities. In order to progress the evolution of medicine, this compelled the engagement of numerous research institutions and organizations dedicated to heart health. Coronavirus-related catastrophes caused a significant number of patients with pre-existing unfavorable disorders to succumb to them, which had an effect on cardiac safety services. As a result of COVID-19's vigorous promotion of its development, the market for cardiac safety services was positively affected overall.
Market Growth Factors
Increase In Research For Biosimilars And Biologics
Numerous businesses are making significant investments in the creation of biologics and biosimilar compounds. In the discovery stage, biologics such peptides, proteins, and monoclonal antibodies make up more than half of the therapeutic candidates. Pharmaceutical and biopharmaceutical businesses are heavily putting money into their research and development as novel biologics are being developed or are in the pipeline. Biosimilars are also less expensive because, being generic versions of patented biologic medications, they are not subject to the same strict regulatory standards.
High Prevalence Of Ech Holter Service Among The General Population
The rise in the number of elderly people and the increasing incidence of cardiovascular disorders are mostly to blame for the ECG Holter's expansion. According to data released by Health System Tracker, heart disease is the top cause of mortality in the United States. These reasons make immediate heartbeat detection and constant heart rate monitoring equipment necessary. In the past few years, the healthcare system has employed ECG monitoring devices to look for any abnormalities in cardiac activity.
Market Restraining Factors
Lack Of Qualified Personnel For Clinical Trials
The R&D outsourcing industry for pharmaceuticals, biotechnology, and medical devices is always changing. To deliver high-quality services, adhere to acceptable laboratory procedures, and keep up with the ongoing developments in medical device and pharmaceutical R&D technologies and techniques, highly skilled experts are needed. As they compete for trained and experienced scientists with biotechnology, pharmaceutical, and medical device businesses as well as research and academic organizations, CROs confront difficulties in attracting and keeping highly skilled personnel.
Type Outlook
Based on type, the cardiac safety services market is bifurcated into integrated and standalone. The integrated segment dominated the cardiac safety services market with the highest revenue share in 2021. These cutting-edge core lab services provide a full range of cardiac safety services, including imaging, TQT, and profile QT tests. In order to help with the real-time evaluation of heart rate and rhythm, they also keep an eye on off-target cardiovascular liabilities and conduct onsite multichannel telemetry under the supervision of licensed nurses.
Type of Service Outlook
On the basis of type of service, the cardiac safety services market is divided into ECG/Holter measurement, blood pressure measurement, cardiovascular imaging, thorough QT studies, and other services. The ECG/Holter measurement segment witnessed the largest revenue share in the cardiac safety services market in 2021. Smartwatches and other personal electronics provide electrocardiogram monitoring. A small, portable gadget called a Holter monitor is used to capture heartbeats. It is employed to identify and evaluate the likelihood of aberrant heartbeats (arrhythmias).
End User Outlook
Based on end user, the cardiac safety services market is categorized into pharmaceutical & biopharmaceutical companies and contract research organizations. The contract research organizations segment procured a substantial revenue share in the cardiac safety services market in 2021. Clinical trials are carried out by Contract Research Organizations (CROs) for the pharmaceutical, medical device, and biotechnology businesses as well as for academic institutions, governmental agencies, and foundations.
Regional Outlook
On the basis of region, the cardiac safety devices is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region acquired the highest revenue share in the cardiac safety services market in 2021. This is due to the region's growing number of clinical studies, which are fueling demands for cardiac safety services. The rising number of people suffering from cardiovascular diseases (CVD) and coronary heart disease (CHD) have accelerated the drug development and research studies in the region.
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Pharmaceutical Product Development, Inc. is the major forerunner in the Cardiac Safety Services Market. Companies such as Koninklijke Philips N.V., Laboratory Corporation of America Holdings, IQVIA Holdings, Inc. are some of the key innovators in Cardiac Safety Services Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Clario, IQVIA Holdings, Inc., Laboratory Corporation of America Holdings, Pharmaceutical Product Development, Inc., SGS S.A., Banook Group, Biotrial Research SAS, Certara, Inc., and Celerion.
Strategies deployed in Cardiac Safety Services Market
Aug-2022: Labcorp acquired RWJBarnabas Health, a network of independent healthcare providers in New Jersey. Through this acquisition, Labcorp planned to offer expanded health plan coverage, enhanced service to rural markets, and the potential for reduced out-of-pocket lab costs for patients.
Jun-2022: The Banook Group expanded its geographical footprint by opening its first US office in Boston, Massachusetts. Through this expansion, Banook aimed to reduce the constraints of time zones and to provide enhanced technical and logistics support to its customers as about 40% of Banook's customers are based in this region. The expansion also allowed the company to offer local support to its 70 current US customers and to grow in the North American market.
Apr-2022: Royal Philips, partnered with Prisma Health, South Carolina's largest non-profit healthcare system. Through this partnership, the companies agreed to help the health system achieve enterprise interoperability, standardize patient monitoring, and drive innovation in enterprise imaging solutions to enhance patient care and improve clinical performance.
Mar-2022: IQVIA unveiled OCE+, the first of several new advancements to its leading life science customer engagement platform. OCE+ adds IQVIA's Next Best recommendation engine to its Orchestrated Customer Engagement (OCE) platform, providing enhanced HCP experiences, improved productivity, and increased ROI. The product uses IQVIA's industry-leading data and advanced analytics to deliver AI-driven recommendations directly into the daily workflows of life sciences commercial teams.
Jan-2022: Clario partnered with ActiGraph, a pioneer and leading provider of activity-sensing wearable technology. From this partnership, Clario expanded its evidence generation platform and portfolio of decentralization technologies and offered ActiGraph technologies to its customers in addition to its suite of eCOA, Precision Motion, Cardiac Safety, Respiratory, Medical Imaging, and Trial Enablement solutions. The partnership also helped clinical trial sites and sponsors to drive up efficiency and accuracy while increasing convenience for study participants.
Dec-2021: Labcorp took over Personal Genome Diagnostics (PGDx), a provider of comprehensive liquid biopsy and tissue-based genomic products and services. From this acquisition, Labcorp aimed to strengthen its next-generation sequencing-based genomic profiling capabilities and accelerate the existing liquid biopsy capabilities.
Nov-2021: Royal Philips acquired Cardiologs, a French medical technology firm. From this acquisition, Royal Philips aimed at expanding its cardiac monitoring and diagnostics portfolio with innovative software technology, electrocardiogram (ECG) analysis, and reporting services.
Sep-2021: The Banook Group acquired Nabios, biotech with strong expertise in cardiac safety assessments in clinical trials of drugs intended for human health. Through this acquisition, the company advanced its steps towards becoming the leader in the cardiac safety market by offering a strong European alternative to those companies operating from North America or India. This acquisition also granted Banook's customers access to new and more competitive services.
Sep-2021: IQVIA collaborated with HealthCore, a leading real-world research organization in the United States. Under the collaboration, the companies focused on advancing real-world evidence (RWE) studies with increased quality and efficiency. The innovative research collaboration focused specifically on real-world studies such as external comparators, pragmatic trials, and enriched studies.
Mar-2021: Certara took over AUTHOR!, a provider of medical writing and statistical analysis of clinical trial data to global pharmaceutical and biotechnology companies. Through this acquisition, Certara enhanced the existing regulatory and biostatistical expertise and helped to fuel the company's strategic expansion in Europe. Additionally, from the acquisition, Certara leveraged AUTHOR!'s seasoned team to provide technology-enabled capabilities to its customers and thus help global clients expertly navigate and accelerate the drug development and regulatory approval process.
Feb-2021: Royal Philips took over BioTelemetry, a leading U.S.-based provider of remote cardiac diagnostics and monitoring. Through this acquisition, Royal Philips expanded its cardiac care portfolio, and its strategy to transform the delivery of care along the health continuum with integrated solutions.
Feb-2021: Philips formed a partnership with SAZ hospital network, a Dutch Hospital network comprising 28 hospitals. Under this partnership, Philips offered advanced patient monitoring and population health management solutions to the SAZ network hospitals. In addition, Philips solutions enabled SAZ to enhance monitoring, observation, and self-management of patients across the care journey, both inside and outside the hospitals.
Mar-2018: Certara introduced Quantitative Systems Pharmacology (QSP) Immuno-oncology Simulator Consortium. The product combines computational modeling and experimental methods to examine the mechanistic relationships between a drug, the biological system, and the disease process. In addition, QSP integrates quantitative drug data with the knowledge of the drug's mechanism of action.
Market Segments covered in the Report:
By Type
By End User
By Type of Service
By Geography
Companies Profiled
Unique Offerings from KBV Research